Erin McCallister

@EMcCallister01

Senior Editor, Head of Clin Dev. & Mkt Access ; mom; Purdue and U of C alum; co-owner . My tweets are my own...

Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @EMcCallister01

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EMcCallister01

  1. proslijedio/la je Tweet
    28. sij

    's Bourla aims for BD over buybacks and remains commited to at least a 6% CAGR over the next five years

    Poništi
  2. 28. sij

    After nearly 12 years, tomorrow is my last day with . I am joining PwC's Health Research Institute next month. It's been an amazing ride and I am looking forward to the next adventure. Give a follow to stay up to date on Clin Dev. Cheers!

    Poništi
  3. proslijedio/la je Tweet
    26. sij

    Biocentury articles are really top notch landscapes with target antigens

    Poništi
  4. proslijedio/la je Tweet
    25. sij

    Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in . Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.

    Poništi
  5. proslijedio/la je Tweet
    25. sij

    Publication of the gene sequence of the Wuhan coronavirus has sparked a race to develop vaccines and drugs. The first could be monoclonal antibodies that are both treatment and prophylaxis.

    Poništi
  6. 25. sij

    Great piece from on recent manufacturing moves, including Deerfield's new CDMO. Manufacturing is a BIG deal in cell and gene therapy btw

    Poništi
  7. proslijedio/la je Tweet
    25. sij

    Roche is looking to make CNS a growth driver to match oncology this next decade. Partnering with small and large companies will be a big part of that.

    Poništi
  8. proslijedio/la je Tweet
    25. sij

    Some biotechs are turning to partnerships to increase gene and cell therapy manufacturing capacity. January saw at least seven manufacturing deals and launches, including a new CDMO from Deerfield and a JV from and Wilson Wolf

    Poništi
  9. proslijedio/la je Tweet
    24. sij

    Here's a round-up of 3 interesting preclinical discoveries, via . Research from . Targets: 4-IBB, alpha-SMA, BCMA, CXCL12, FAP and more.

    Poništi
  10. proslijedio/la je Tweet
    24. sij

    Guest Commentary: EMD Serono and Accelerated Cure Project argue a new, more collaborative model is needed to effectively integrate the patient voice into R&D

    Poništi
  11. proslijedio/la je Tweet
    23. sij

    An oral spinal muscular atrophy () could give patients/parents/physicians another option. If efficacy is good and it is less expensive, will payers push parents to select risdiplam over Zolgensma, a potential cure? Will Biogen respond by cutting the price of Spinraza?

    Poništi
  12. proslijedio/la je Tweet
    20. sij

    Great article from on developments in manufacturing, yields, targeting and dosing needed take gene therapy to next level ⬇️

    Poništi
  13. proslijedio/la je Tweet
    23. sij

    Really interesting article

    Poništi
  14. proslijedio/la je Tweet
    23. sij

    Good read from my colleague -> 4 big pharma companies won bids for five off-patent products, taking an average price cut of 82%...

    Poništi
  15. proslijedio/la je Tweet
    22. sij

    Moderna, Novavax among biotechs working on Wuhan virus -- but vaccine at least a year out

    Poništi
  16. proslijedio/la je Tweet
    17. sij

    . decision strengthens UC’s patent position in Europe over Broad -- ensuring that the CRISPR IP landscape is going to look much different in Europe than the U.S. 's explains

    Poništi
  17. proslijedio/la je Tweet
    16. sij

    reminds us companies are only one part of a big system. It’s not just about lower list prices.

    Poništi
  18. proslijedio/la je Tweet
    14. sij

    crashes party as Treasury final rules scale back definition of genetic data that could trigger review of foreign investments in U.S. companies that collect genetic information. 's explains:

    Poništi
  19. proslijedio/la je Tweet
    13. sij

    deal underwhelms investors who appear to question choice of as partner but $900M upfront is 2nd largest in past year for an EU biotech. via 's

    Poništi
  20. 12. sij

    Newco from Borisy, Nallicheri, and Horning will dev, launch innovative drugs at radically lower prices, and they'll work with other stakeholders in the system to help make sure those those cheaper drugs get used, bring down costs

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·